Merck has high expectations for the next-generation oncology treatment, and justifiably so. Last month, it presented slam-dunk data at the American Association of Cancer Research (AACR): in a Phase III combination trial, Keytruda plus chemotherapy decreased the risk of death by 51% for newly-diagnosed patients with the advanced, non-squamous type of non-small cell lung cancer (NSCLC) compared to chemotherapy alone.
